Abstracts tagged "osteoclasts and rheumatoid arthritis (RA)"

Abstract Number: 1824 • 2018 ACR/ARHP Annual Meeting
Osteoclast Derived-Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss
Olivier Peyruchaud¹, Sacha Flammier¹, Fanny Bourguillault¹, Francois Duboeuf¹, Gabor Tigyi², Irma Machuca-Gayet¹ and Fabienne Coury¹, ¹INSERM UMR1033, Lyon, France, ²Department of Physiology, University of Tennessee, Memphis, TN
Background/Purpose: Rheumatoid arthritis (RA) patients in sustained clinical remission or low disease activity may continue to accrue periarticular bone erosions despite control of inflammation. Osteoclasts…
Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Pooja Naik¹, Jing Shi², Felipe Andrade³ and Erika Darrah⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…
Abstract Number: 53 • 2017 ACR/ARHP Annual Meeting
Poly-γ-Glutamic Acid Inhibits RANKL- Induced Osteoclast Differentiation and Prevents Bone Destruction in Rheumatoid Arthritis: Human and CIA Mouse Model
Bitnara Lee¹, Jong-Dae Ji² and Tae-Hwan Kim¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Rheumatology, Korea University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disease that is characterized by chronic inflammation and bone destruction. Osteoclasts, which are bone-resorbing cells, are generally known…
Abstract Number: 1944 • 2017 ACR/ARHP Annual Meeting
A Dual Role for IL-23 Receptor Signaling in Normal Bone Remodeling Versus Inflammation-Mediated Bone Damage during Arthritis
Wida Razawy¹, Marijke Koedam², Patrick Asmawidjaja³, Anne-Marie Otten-Mus⁴, Bram van der Eerden² and Erik Lubberts³, ¹Rheumatology and Immunology, Erasmus MC, Rotterdam, Netherlands, ²Internal Medicine, Erasmus MC, Rotterdam, Netherlands, ³Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
Background/Purpose: The interleukin (IL)-23/IL-17A immune pathway is critical for the development of autoimmune arthritis. Systemic exposure of IL-23 induced chronic arthritis, increased osteoclast differentiation and…
Abstract Number: 1449 • 2016 ACR/ARHP Annual Meeting
The Efficiency of the Regulation of Ca2+ Entry through Calcium Release-Activated Calcium Channel in the Treatment of Rheumatoid Arthritis
Shuang Liu¹, Hitoshi Hasegawa², Takeshi Kiyoi³, Tatsuya Sawasaki⁴ and Kazutaka Maeyama⁵, ¹Dept. Pharmacology,, Ehime University Graduate School of Medicine, Toon-shi, Japan, ²Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan, ³Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, ⁴Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, Japan, ⁵Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan
Background/Purpose: The regulation of Ca2+ entry by targeting a store-operated calcium release-activated channel (CRAC), known as ORAI, has shown benefits in the treatment of rheumatoid…
Abstract Number: 580 • 2016 ACR/ARHP Annual Meeting
Preferential Distribution of M1 Monocytes in Anti-Cyclic Citrullinated Peptide Antibody Positive Patients with Rheumatoid Arthritis
Shoichi Fukui¹, Naoki Iwamoto², Toshimasa Shimizu², Masataka Umeda², Ayako Nishino³, Yoshiro Horai², Tomohiro Koga⁴, Shin-ya Kawashiri⁵, Kunihiro Ichinose⁶, Yasuko Hirai², Mami Tamai⁶, Hideki Nakamura⁵, Tomoki Origuchi⁷ and Atsushi Kawakami⁴, ¹Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, ⁴Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: In rheumatoid arthritis (RA), bone erosions are caused mainly by osteoclasts. Osteoclasts are derived from monocytes and macrophages (MoMa). MoMa consists of different subtypes…
Abstract Number: 1156 • 2015 ACR/ARHP Annual Meeting
Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis
MIN-YOUNG JUNG¹, Hae-Rim Kim², HYUN-SOOK KIM³, HO-YOUN KIM¹ and Sang Heon Lee⁴, ¹Konkuk university hospital, Seoul, South Korea, ²Division of Rheumatology, Konkuk University School of Medicine, Seoul, South Korea, ³Soonchenhyang university school of medicine, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea
Background/Purpose: This study aimed to determine the regulatory effect of Th17 cytokines on osteoclastogenesis in rheumatoid arthritis (RA). Methods: The expression of interleukin (IL)-17 and…
Abstract Number: 2707 • 2015 ACR/ARHP Annual Meeting
An in Vitro Bovine Bone Chip Model with Micro-CT: A Model for the Assessment of Autoantibody Mediated Bone Resorption
Manpreet Kaur Sethi¹, Anand Dusad¹, Andy Hollins², Carlos D. Hunter³, Michael J. Duryee³, Ted R. Mikuls², Geoffrey M. Thiele⁴ and Ellen M. Gravallese⁵, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Lazare Research Bldg Ste 223, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are specific to rheumatoid arthritis (RA) and are associated with disease severity. Although ACPAs are associated with disease progression, mechanisms…
Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Lei Zhou¹, Robert Sikorski¹, Seema Rogers¹, Stefan Costin², Mariusz Korkosz³, Maria Jaraczewska-Baumann⁴, Péterfai Éva⁵, Bernadette Rojkovich⁶, Janos Bartalos⁷, Emma Masteller¹, Hong Xiang¹, Brian Wong¹ and Julie Hambleton¹, ¹Five Prime Therapeutics, Inc., South San Francisco, CA, ²PRA Heath Sciences, Berlin, Germany, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴MedPolonia Sp. z o.o, Poznan, Poland, ⁵Drug Research Center, Balatonfüred, Hungary, ⁶Hospitaller Brothers of St. John of God, Budapest, Hungary, ⁷PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
Abstract Number: 2820 • 2014 ACR/ARHP Annual Meeting
Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation
Nida Meednu¹, Hengwei Zhang², Teresa Owen³, Lianping Xing⁴ and Jennifer H. Anolik⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose Rheumatoid arthritis (RA) is a systemic autoimmune disease that often leads to joint damage, a process mediated by an imbalance between bone resorption and…
Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting
Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Anita Boyapati¹, Jérôme Msihid², Emmanuelle Cousin³, Ling Cai⁴, Janet van Adelsberg¹, Jennifer D Hamilton¹, Neil Graham⁵, Tanya Momtahen⁶ and Stefano Fiore⁷, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi R&D, France, Chilly-Mazarin, NJ, France, ³Sanofi R&D, France, Chilly-Mazarin, France, ⁴Sanofi R&D, China, Beijing, China, ⁵Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Sanofi, Bridgewater, NJ, ⁷Distinct Project Unit, Sanofi, Bridgewater, NJ
Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
Abstract Number: 323 • 2014 ACR/ARHP Annual Meeting
Anti-Inflammatory Marine Compound, Lyy-B2, Ameliorates Rheumatoid Arthritis through Inhibition of Osteoclast Differentiation
Yen-You Lin¹, Hsin-Pai Lee^1,2, Shi-Ying Huang¹, Han-Chun Hung³, Chien-Wei Feng³, Chun-Hong Chen³, Jui-Hsin Su^4,5, Ping-Jyun Sung^4,5, Jyh-Horng Sheu^1,3, Yen-Hsuan Jean² and Zhi-Hong Wen^1,3, ¹Department of Marine Biotechnology and Resources, Asia-Pacific Ocean Research Center, National Sun Yat-Sen University, Kaohsiung, Taiwan, ²Section of Orthopedic Surgery, Pingtung Christian Hospital, Pingtung, Taiwan, ³Doctoral Degree Program in Marine Biotechnology, National Sun Yat-Sen University, Kaohsiung, Taiwan, ⁴Graduate Institute of Marine Biotechnology, National Dong Hwa University, Pingtung, Taiwan, ⁵Taiwan Coral Research Center, National Museum of Marine Biology & Aquarium, Pingtung, Taiwan
Background/Purpose: Osteoclasts are multinucleated giant cells of macrophage/monocyte lineage, and are believed to play major roles in joint destruction caused by rheumatoid arthritis (RA). Nuclear…
Abstract Number: 1384 • 2013 ACR/ARHP Annual Meeting
Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)
Yoshiya Tanaka¹, Tsutomu Takeuchi², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désiréé van der Heijde⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Keio University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RANKL is an essential factor for osteoclast differentiation and activation. Denosumab, a fully human monoclonal IgG2 antibody, is a potent inhibitor of RANKL and…
Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting
Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts
Sandra Mueller-Schmucker¹, Roland Axmann¹, Sonja Herman², Mario Zaiss¹, Manuela Le Bars³, Thomas Harrer¹ and Georg A. Schett⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Bristol-Myers Squibb, Rueil Malmaison, France, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…
Abstract Number: 329 • 2012 ACR/ARHP Annual Meeting
The SYK Inhibitor, Fostamatinib, Administered Alone or in Combination with Methotrexate in Rat Collagen-Induced Arthritis, Reduces Bone Erosions, Biomarkers of Cartilage/Bone Destruction, and Synovial Osteoclastogenic Cytokines
Polly Pine¹, Ayodele Apatira¹, Betty Y. Chang¹, Nathan Schoettler², Elliott B. Grossbard³ and Ernest Brahn², ¹Pharmacology, Rigel Pharmaceuticals, So San Francisco, CA, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Rigel Pharmaceuticals, So San Francisco, CA
Background/Purpose: Spleen tyrosine kinase (SYK) is expressed in hematopoietic cells and is a major downstream regulator of signaling through Fcγ and immunoglobulin receptors as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].